

Primer sequences	Annealing temperature
<b>NKILA</b> Forward, 5'-AACCAAACCTACCCACAACG-3' Reverse, 5'-ACCACTAAGTCATCCCAGGTG-3'	64°C
<b>NEAT1</b> Forward, 5'- CCTGCCTTCTTGTGCGTTTC -3' Forward, 5'- CTTGTACCCTCCCAGCGTTT -3'	64°C
<b>MALAT1</b> Forward, 5'-TGGTGTCGAGGTCTTTGGTG-3' Forward, 5'-AAAAGCCCTCTCAGCCACTC-3'	60°C
<b>MIAT</b> Forward, 5'-TACTCCCTCCTCACCTGCTC-3' Forward, 5'-CCATCCTTGTTCCCTGTCCCC-3'	60°C
<b>GAPDH</b> Forward, 5'-GGTGGTCTCCTCTGACTTCAA -3' Reverse, 5'-GTTGCTGTAGCCAAATTCGTTGT -3'	64°C

**Table 1:** Primer sequences to amplify the lncRNAs NKILA, NEAT1, MALAT1, and MIAT, with GAPDH used as an internal control.

Variable	T2DM patients (%)	Controls subjects (%)
<b>Total no.</b>	200 (100)	200 (100)
<b>Sex</b>		
Male	136 (68)	140 (70)
Female	64 (32)	60 (30)
<b>Age at diagnosis (years)</b>		
≤ 40	94 (47)	100 (44)
> 40	106 (53)	100 (56)
<b>HTN</b>		

Yes	122 (61)
No	78 (39)
<b>Nephropathy</b>	
Yes	97 (48.5)
No	103 (51.5)
<b>Weight loss</b>	
Yes	94 (47)
No	106 (53)
<b>Fatigue</b>	
Yes	95 (47.5)
No	105 (52.5)
<b>Slow wound healing</b>	
Yes	84 (42)
No	116 (58)
<b>Retinopathy</b>	
Yes	67 (33.5)
No	133 (76.5)
<b>Loss of appetite</b>	
Yes	91 (45.5)
No	109 (54.5)
<b>Smoking status</b>	
Yes	92 (46)
No	108 (54)
<b>Alcoholism</b>	
Yes	102 (51)
No	98 (49)

**Table 2:** Demographic and clinical characteristics of type 2 diabetes mellitus patients and healthy controls.